The growth of the EPS is critical in understanding the current valuation of Aerie Pharmaceuticals. The EPS growth rate, as it is typically called, is usually expressed as a percentage, which at this time is hard to estimate, but the year over year change has been -94.38%. The higher the EPS growth rate, the higher the value that is added to shareholders and a good reflection on the performance of the management at Aerie Pharmaceuticals.
Aerie Pharmaceuticals trades as part of the drug manufacturers industry and is part of the healthcare sector. The company CEO is Vicente Anido. Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is engaged in the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.
Previous Intraday Performance:
The AERI shares had a previous change of -2.87% which opened at 41.04 and closed at 39.89. It moved to an intraday high of 41.22 and a low of 39.12.
SeekingAlpha: Updating My Aerie Pharmaceuticals Short
Historical Performance:
Over the last five trading days, AERI shares returned -5.25% and in the past 30 trading days it returned -31.67%. Over three months, it changed -35.09%. In one year it has changed -34.55% and within that year its 52-week high was 74.75 and its 52-week low was 38.50. AERI stock is 3.61% above its 52 Week Low.
Our calculations result in a 200 day moving average of 57.32 and a 50 day moving average of 52.37. Right now, AERI stock is trading -30.41% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.
SeekingAlpha: Updating My Aerie Pharmaceuticals Short
Liquidity:
The company has a market cap of $1.8b with 45.5m shares outstanding and a float of 44.7m shares. Trading volume was 727,832 shares and has experienced an average volume of 666,229 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is good.
Earnings:
The last annual reported EPS for Aerie Pharmaceuticals was -4.1 which ended on 31st of December 2017. Based on 3 analyst estimates, the consensus EPS for the next quarter is -1.33.
Below was the last reported quarterly earnings per share:
09-30-2018: -1.73
06-30-2018: -1.40
03-31-2018: -1.05
12-31-2017: -1.38
Base on our calculations, the intrinsic value per share is 126.99, which means it might be undervalued and has a margin of safety of 68.59%
Indicators Also to Watch:
Based on the latest filings, there is 1.80% of insider ownership and 82.40% of institutional ownership. Short-interest was 0, which was 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio was 0.00.
I calculated the beta to be 0.74
PR Newswire: Bancorp 34, Inc. Announces Adoption Of Repurchase Program
Fundamental Numbers:
Based on last reported financials, the company’s return on equity is -112.01%, return on assets is -77.88%, price-to-sales is 191.96 and price-to-book is 6.75.
Company Score Card:
Results are out of six:
5 : Growth Expectations Result
6 : Financial Safety Result
0 : Past Performance Result
2 : Valuation Result
0 : Dividend Safety Result
3 : Overall Result
Related Tags: AERI, Aerie Pharmaceuticals, Drug Manufacturers, Healthcare
